114,95 €
114,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
114,95 €
Als Download kaufen
114,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
114,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
57 °P sammeln
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in Medicinal Chemistry and Chemical Biology. As Medicinal Chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design.
- Geräte: eReader
- ohne Kopierschutz
- eBook Hilfe
- Größe: 22.7MB
Andere Kunden interessierten sich auch für
- Nathan KeighleyMiraculous Medicines and the Chemistry of Drug Design (eBook, ePUB)21,95 €
- Nina DragicevicInvasomes as Drug Nanocarriers for Innovative Pharmaceutical Dosage Forms (eBook, ePUB)21,95 €
- Mikhail DarkhovskiyMolecular Recognition in Pharmacology (eBook, ePUB)68,95 €
- Victor E. MarquezThe Ups and Downs in Drug Design (eBook, PDF)114,95 €
- Raymond S. OchsBiochemistry (eBook, ePUB)114,95 €
- John G. D'AngeloSynthetic Organic Chemistry and the Nobel Prize Volume 1 (eBook, ePUB)21,95 €
- Purification of Biotechnological Products (eBook, ePUB)171,95 €
-
-
-
The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in Medicinal Chemistry and Chemical Biology. As Medicinal Chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 474
- Erscheinungstermin: 15. November 2021
- Englisch
- ISBN-13: 9781000462944
- Artikelnr.: 62649400
- Verlag: Taylor & Francis
- Seitenzahl: 474
- Erscheinungstermin: 15. November 2021
- Englisch
- ISBN-13: 9781000462944
- Artikelnr.: 62649400
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Dr. Victor E. Marquez After one year of postdoctoral studies at the National Cancer Institute (NCI)/National Institutes of Health (NIH), Dr. Marquez returned to Venezuela as Research Director of Cosmos Laboratories. In 1977, he rejoined the NCI as a Visiting Scientist, and from 1999 to 2009 he was Chief of the Laboratory of Medicinal Chemistry. In 2008, Dr. Marquez was named Maryland Chemist of the Year, and in 2010 he was inducted into the Medicinal Chemistry Hall of Fame. Dr. Marquez retired as Scientist Emeritus after 32 years of service.
1. STRUCTURE-ACTIVITY RELATIONSHIPS (SAR). 2. BRAIN ANTITUMOR AGENTS: THE
STORY OF SPIROMUSTIN. 3. PRIVILEGED DRUG SCAFFOLDS: THE STORY OF LC-6 AND
PYRIDINOLCARBAMATE. 4. CYTIDINE DEAMINASE: PART 1-THE CONCEPT OF
TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE. 5. CYTIDINE
DEAMINASE: PART 2-LESSONS FROM NATURE'S TRANSITION STATE INHIBITORS. 6.
TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE
(TAD). 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS. 8. THE AIDS ERA:
SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE.
9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV
AND ANTIVIRAL DRUGS. 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE. 11.
EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE. 12. ZEBULARINE AS AN
EPIGENETIC ANTICANCER AGENT. 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN
EPIGENETIC ANTICANCER AGENT. 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES:
CHEMISTRY. 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 1). 16.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 2)-MORE ON
KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT. 17. BICYCLO[3.1.0]HEXANE
NUCLEOSIDES: BIOLOGY (PART THREE)-INVESTIGATION OF MORE EXOTIC TARGETS. 18.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMICAL VARIATIONS ON A COMMON THEME.
19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): A
PHARMACOPHORE-GUIDED APPROACH. 20. DIACYLGLYCEROL LACTONES AND PROTEIN
KINASE C (PKC): TRANSITION FROM A PHARMACOPHORE-GUIDED APPROACH TO A
RECEPTOR-GUIDED APPROACH.
STORY OF SPIROMUSTIN. 3. PRIVILEGED DRUG SCAFFOLDS: THE STORY OF LC-6 AND
PYRIDINOLCARBAMATE. 4. CYTIDINE DEAMINASE: PART 1-THE CONCEPT OF
TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE. 5. CYTIDINE
DEAMINASE: PART 2-LESSONS FROM NATURE'S TRANSITION STATE INHIBITORS. 6.
TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE
(TAD). 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS. 8. THE AIDS ERA:
SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE.
9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV
AND ANTIVIRAL DRUGS. 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE. 11.
EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE. 12. ZEBULARINE AS AN
EPIGENETIC ANTICANCER AGENT. 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN
EPIGENETIC ANTICANCER AGENT. 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES:
CHEMISTRY. 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 1). 16.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 2)-MORE ON
KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT. 17. BICYCLO[3.1.0]HEXANE
NUCLEOSIDES: BIOLOGY (PART THREE)-INVESTIGATION OF MORE EXOTIC TARGETS. 18.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMICAL VARIATIONS ON A COMMON THEME.
19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): A
PHARMACOPHORE-GUIDED APPROACH. 20. DIACYLGLYCEROL LACTONES AND PROTEIN
KINASE C (PKC): TRANSITION FROM A PHARMACOPHORE-GUIDED APPROACH TO A
RECEPTOR-GUIDED APPROACH.
1. STRUCTURE-ACTIVITY RELATIONSHIPS (SAR). 2. BRAIN ANTITUMOR AGENTS: THE
STORY OF SPIROMUSTIN. 3. PRIVILEGED DRUG SCAFFOLDS: THE STORY OF LC-6 AND
PYRIDINOLCARBAMATE. 4. CYTIDINE DEAMINASE: PART 1-THE CONCEPT OF
TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE. 5. CYTIDINE
DEAMINASE: PART 2-LESSONS FROM NATURE'S TRANSITION STATE INHIBITORS. 6.
TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE
(TAD). 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS. 8. THE AIDS ERA:
SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE.
9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV
AND ANTIVIRAL DRUGS. 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE. 11.
EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE. 12. ZEBULARINE AS AN
EPIGENETIC ANTICANCER AGENT. 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN
EPIGENETIC ANTICANCER AGENT. 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES:
CHEMISTRY. 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 1). 16.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 2)-MORE ON
KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT. 17. BICYCLO[3.1.0]HEXANE
NUCLEOSIDES: BIOLOGY (PART THREE)-INVESTIGATION OF MORE EXOTIC TARGETS. 18.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMICAL VARIATIONS ON A COMMON THEME.
19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): A
PHARMACOPHORE-GUIDED APPROACH. 20. DIACYLGLYCEROL LACTONES AND PROTEIN
KINASE C (PKC): TRANSITION FROM A PHARMACOPHORE-GUIDED APPROACH TO A
RECEPTOR-GUIDED APPROACH.
STORY OF SPIROMUSTIN. 3. PRIVILEGED DRUG SCAFFOLDS: THE STORY OF LC-6 AND
PYRIDINOLCARBAMATE. 4. CYTIDINE DEAMINASE: PART 1-THE CONCEPT OF
TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE. 5. CYTIDINE
DEAMINASE: PART 2-LESSONS FROM NATURE'S TRANSITION STATE INHIBITORS. 6.
TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE
(TAD). 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS. 8. THE AIDS ERA:
SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE.
9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV
AND ANTIVIRAL DRUGS. 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE. 11.
EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE. 12. ZEBULARINE AS AN
EPIGENETIC ANTICANCER AGENT. 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN
EPIGENETIC ANTICANCER AGENT. 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES:
CHEMISTRY. 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 1). 16.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 2)-MORE ON
KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT. 17. BICYCLO[3.1.0]HEXANE
NUCLEOSIDES: BIOLOGY (PART THREE)-INVESTIGATION OF MORE EXOTIC TARGETS. 18.
BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMICAL VARIATIONS ON A COMMON THEME.
19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): A
PHARMACOPHORE-GUIDED APPROACH. 20. DIACYLGLYCEROL LACTONES AND PROTEIN
KINASE C (PKC): TRANSITION FROM A PHARMACOPHORE-GUIDED APPROACH TO A
RECEPTOR-GUIDED APPROACH.